Themis Medicare Q2 Results 2026: PAT ₹7 Cr (turned profitable)
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹90Cr
- +15.1% YoY
- +3.2% QoQ
- Net profit
- ₹7Cr
- Turned profitable YoY
- −71.3% QoQ
- Margin
- 6.2%
- +10.2 pp YoY
- +66.5 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Themis Medicare Ltd Q2 FY27 key numbers
- Revenue
- API business revenue grew 71% to ₹20 crore in Q2 FY27, driving overall growth.
As stated in Themis Medicare Ltd's Q2 FY27 investor presentation · published 15 Nov 2026. Reported figures, not investment advice.
Based on Themis Medicare Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Q2 FY27 EBITDA: ₹5.58 crore, up from a loss of ₹3.09 crore in Q2 FY26; EBITDA margin 6.22% vs. -3.96% YoY.
From Themis Medicare Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.
How did Themis Medicare's revenue grow in the September 2026 quarter?
- Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8).
- API business revenue grew 71% to ₹20 crore in Q2 FY27, driving overall growth (Page 5).
- Formulations business steady at ₹69 crore in Q2 FY27 (Page 5).
- For H1 FY27, net revenue stood at ₹176.70 crore, a 0.6% increase from ₹175.57 crore in H1 FY26 (Page 9).
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
What happened to Themis Medicare's margins in Q2 FY27?
Q2 FY27 EBITDA: ₹5.58 crore, up from a loss of ₹3.09 crore in Q2 FY26; EBITDA margin 6.22% vs. -3.96% YoY
Locked: what Themis Medicare Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Themis Medicare planning?
- It highlights three state-of-the-art manufacturing facilities: Formulations at Haridwar, Synthetic APIs at Hyderabad, and Synthetic APIs at Vapi.
- Capacities mentioned: Tablets - 520 million units, Ointments - 9 million tubes, Ampoules - 36 million, Vials - 12 million, Pre-filled syringes - 6 million, Synthetic API capacities at 120 MT (Hyderabad) and 191 MT (Vapi).
- Under "Our Aspirations" (Page 18), the company plans expansion in new Rest of World markets (0-3 years) and entry into regulated markets in Phase II (3-5 years).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Themis Medicare raising money or cutting debt?
Balance sheet data shows a slight decrease in long-term borrowings from Rs. 21.86 Cr (Mar’26) to Rs. 21.44…
Locked: what Themis Medicare Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Themis Medicare's order book?
See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.
Themis Medicare Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Themis Medicare Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 90 | 78 | +15.1% | 87 | +3.2% |
| Operating profit (EBITDA) | 6 | -3 | — | -52 | — |
| Operating margin | 6.2% | -4% | +10.2 pp | -60.3% | +66.5 pp |
| Profit before tax | 5 | -5 | — | 36 | -86% |
| Net profit (PAT) | 7 | -4 | — | 25 | -71.3% |
| EPS (₹) | 0.77 | -0.39 | — | 2.67 | -71.2% |
Source: Themis Medicare Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹87 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
- Alpa Laboratorie (Q2 FY27)
Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aarey Drugs (Q2 FY27)
Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs . Key results statement takeaways from Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q2 FY27 results?
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Q2 FY27 EBITDA: ₹5.58 crore, up from a loss of ₹3.09 crore in Q2 FY26; EBITDA margin 6.22% vs. -3.96% YoY.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹929 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.